文献速递妇科生殖医学

早期子宫内膜癌保守治疗女性的妊娠与活产机会:系统综述与Meta分析

Chances of pregnancy and live birth among women undergoing conservative management of early-stage endometrial cancer: a systematic review and meta-analysis.
PubMed 文献 · Hum Reprod Update · 2022-01-01

该研究遵循PRISMA推荐,检索了PubMed、Embase和Cochrane Library(截至2021年6月13日),纳入46项研究、861例临床IA期高分化子宫内膜样子宫内膜癌接受保守治疗(CMEC)的女性。随机效应Meta分析显示,接受孕激素为基础CMEC的女性妊娠机会为26.7%(95%CI 21.3-32.3;I²=53.7%),活产机会为20.5%(95%CI 15.7-25.8;I²=40.2%)。

要点

  • 孕激素为基础CMEC后妊娠机会26.7%(95%CI 21.3-32.3),活产机会20.5%(95%CI 15.7-25.8)。
  • 完全缓解率79.7%,其中35.3%在随访期间复发。
  • 286次妊娠中69.4%活产,9%为多胎,66.7%通过生育治疗获得。

核心结论

  • 孕激素为基础CMEC对于希望保留生育功能的临床IA期高分化子宫内膜样子宫内膜癌女性可行,但仅约五分之一估计能活产,仍有改善空间。
  • 作者认为,需要进一步研究预后驱动的选择、宫腔镜切除和长期监测以改善CMEC的生殖结局。

研究设计与样本

  • 系统综述与Meta分析,遵循PRISMA推荐,检索PubMed、Embase和Cochrane Library自建库至2021年6月13日。
  • 纳入标准:临床IA期高分化子宫内膜样子宫内膜癌(EEC)女性、为保留生育功能接受CMEC、报告CMEC后妊娠和/或活产频率。
  • 排除标准:无法分离/提取目标结局数据、持续/复发疾病的二线CMEC、存在同步肿瘤的CMEC、病例报告、非原创或重复数据、非英文文献。
  • 共1275条唯一记录,133篇全文评估,最终纳入46项研究,纳入861例接受CMEC的EEC女性。
  • 采用随机效应Meta分析,并进行调节分析和敏感性分析;研究质量采用专门工具评估。

主要发现

  • 除3项研究外,其余研究均报告孕激素为基础治疗(93.5%;836例女性)。
  • 完全缓解率79.7%,其中35.3%在随访期间复发。
  • CMEC后获得286次妊娠,其中69.4%活产(9%为多胎),66.7%通过生育治疗获得。
  • 孕激素为基础CMEC女性妊娠机会26.7%(95%CI 21.3-32.3;I²=53.7%;42项研究,826例女性),活产机会20.5%(95%CI 15.7-25.8;I²=40.2%;39项研究,650例女性)。
  • 调节分析中,样本量、平均年龄、发表年份、研究设计和质量评分与孕激素为基础CMEC的结局无关;平均随访时长(月)与妊娠机会(回归系数B=0.003;95%CI 0.001-0.005;P=0.006)和活产机会(B=0.005;95%CI 0.003-0.007;P<0.001)正相关。

关键数值与推荐

  • 临床IA期高分化子宫内膜样子宫内膜癌(EEC)女性接受CMEC以保留生育功能。
  • 孕激素为基础CMEC的妊娠机会26.7%(95%CI 21.3-32.3;I²=53.7%;42项研究,826例女性)。
  • 孕激素为基础CMEC的活产机会20.5%(95%CI 15.7-25.8;I²=40.2%;39项研究,650例女性)。
  • 完全缓解率79.7%,复发率35.3%。
  • 286次妊娠中活产69.4%,多胎9%,生育治疗获得66.7%。

临床怎么用

  • 作者认为孕激素为基础CMEC对于希望保留生育功能的临床IA期高分化子宫内膜样子宫内膜癌女性可行,但仅约五分之一估计能活产,仍有改善空间。
  • 作者认为需要进一步研究预后驱动的选择、宫腔镜切除和长期监测以改善CMEC的生殖结局。

局限性

  • 敏感性分析中仅纳入年龄≤35岁女性、孕激素联合宫腔镜切除或随访至少3年的研究亚组活产机会最高,提示这些因素影响结局。
  • 作者认为需要进一步研究预后驱动的选择、宫腔镜切除和长期监测以改善CMEC的生殖结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endometrial cancer is common and usually occurs after menopause, but the number of women diagnosed during reproductive age is increasing. The standard treatment including hysterectomy is effective but causes absolute uterine factor infertility. In order to avoid or postpone surgery, conservative management of endometrial cancer (CMEC) has been proposed for younger women who want to retain their fertility. OBJECTIVE AND RATIONALE: The main objective of this study was to estimate the chances of pregnancy and live birth for women with early-stage endometrial cancer (EEC) who are managed conservatively for fertility preservation. SEARCH METHODS: The PRISMA recommendations for systematic reviews and meta-analyses were followed. Structured searches were performed in PubMed, Embase and the Cochrane Library, from inception until 13 June 2021. Inclusion was based on the following criteria: group or subgroup of women with Clinical Stage IA, well-differentiated, endometrioid endometrial cancer (from now on, EEC); CMEC for fertility preservation; and reported frequencies of women achieving pregnancy and/or live birth after CMEC. The following exclusion criteria applied: impossibility to isolate/extract outcome data of interest; second-line CMEC for persistent/recurrent disease; CMEC in the presence of synchronous tumours; case reports; non-original or duplicated data; and articles not in English. Qualitative synthesis was performed by means of tabulation and narrative review of the study characteristics. Study quality was assessed with an ad hoc instrument and several moderator and sensitivity analyses were performed. OUTCOMES: Out of 1275 unique records, 133 were assessed in full-text and 46 studies were included in the review. Data from 861 women with EEC undergoing CMEC were available. Progestin-based treatment was reported in all but three studies (93.5%; 836 women). Complete response to treatment was achieved in 79.7% of women, with 35.3% of them having a disease recurrence during follow-up. Of 286 pregnancies obtained after CMEC; 69.4% led to live birth (9% of them multiple births) and 66.7% were achieved through fertility treatment. Based on random-effects meta-analyses, women treated with progestin-based CMEC have a 26.7% chance of achieving pregnancy (95% CI 21.3-32.3; I2 = 53.7%; 42 studies, 826 women) and a 20.5% chance to achieve a live birth (95% CI 15.7-25.8; I2 = 40.2%; 39 studies, 650 women). Sample size, average age, publication year, study design and quality score were not associated with the outcomes of progestin-based CMEC in moderator analyses with meta-regression. However, mean follow-up length (in months) was positively associated with the chances of pregnancy (regression coefficient [B] = 0.003; 95% CI 0.001-0.005; P = 0.006) and live birth (B = 0.005; 95% CI 0.003-0.007; P < 0.001). In sensitivity analyses, the highest chances of live birth were estimated in subsets of studies including only women of age 35 or younger (30.7%), the combination of progestins with hysteroscopic resection (30.7%), or at least 3 years of follow-up (42.4%). WIDER IMPLICATIONS: Progestin-based CMEC is viable for women with well-differentiated, Clinical Stage 1A, endometrioid endometrial cancer who want to preserve their fertility, but there is room for improvement as only one-fifth of them are estimated to achieve live birth according to this meta-analysis. Further investigations on prognosis-driven selection, hysteroscopic resection and long-term surveillance are arguably needed to improve the reproductive outcomes of CMEC.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Herrera Cappelletti E, Humann J, Torrejón R, et al. Chances of pregnancy and live birth among women undergoing conservative management of early-stage endometrial cancer: a systematic review and meta-analysis. Hum Reprod Update. 2022. PMID: 34935045. doi:10.1093/humupd/dmab041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。